Exact Sciences Corporation raised revenue guidance for the full year 2023. For the period, the company expects revenue to be in the range of $2.476 billion - $2.486 billion, assuming: Screening revenue of $1.848 billion - $1.853 billion, precision Oncology revenue of $622 million - $627 million, and COVID-19 testing revenue of $6 million compared to previous revenue guidance of $2.441 billion - $2.466 billion, which assumed screening revenue of $1.820 billion - $1.835 billion, precision Oncology revenue of $615 million - $625 million, and COVID-19 testing revenue of $6 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
44.4 USD | -2.30% | -5.40% | -39.88% |
May. 24 | Sector Update: Health Care Stocks Advance Pre-Bell Friday | MT |
May. 24 | Exact Sciences to Present New Data at Oncology Annual Meeting Confirming Prognostic Value of Breast Cancer Test | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.88% | 8.39B | |
+1.15% | 3.32B | |
+5.78% | 2.48B | |
-19.81% | 2.06B | |
-23.28% | 1.59B | |
+35.19% | 1.15B | |
-7.21% | 704M | |
+11.67% | 678M | |
-29.18% | 508M | |
-6.86% | 273M |
- Stock Market
- Equities
- EXAS Stock
- News Exact Sciences Corporation
- Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023